FFR expresses the blood flow in the presence of a coronary artery stenosis as a fraction of the normal blood flow and gives information regarding the functional significance of the lesion. FFR-guided PCI has been demonstrated superior to an angiography-guided PCI and over medical therapy alone. Practice European guidelines support the use of FFR to complement coronary angiography with the highest degree of recommendation (Class IA) for the assessment of coronary stenosis before undertaking myocardial revascularization, FFR guidance is also being implemented to indicate or guide CABG and multiple coronary lesions in PCI (IIa, B)
The pressure-wire-measured FFR
is time-consuming and expensive.
Angiography-based FFR System without adenosine
or other vasodilator treatments significantly
saves operation time and expense
as well as enhances the operation safety.
From 20 minutes+ to 2-3 minutes，
With CAG and real-time pressure input
Lower radiation dose for surgeons
and better recovery for patients
Lower general Cost by reducing the operation cost
and by achieving the primary composite endpoint
consists of death, myocardial infarction,
Suzhou Rainmed Medical Technology Co., Ltd. is a high-tech enterprise specializing in the development of accurate diagnosis and treatment of cardiovascular diseases. The company has independent development capacity for medical devices with clinically approved quality. Rainmed has obtained more than 20 patents. The product has been clinically recognized and approved by a number of medical facilities in China and abroad.